| Literature DB >> 34956491 |
Shuying Yang1,2, Huanhuan Yan1, Youqian Wu3, Bing Shan4, Dongheng Zhou1, Xiaolan Liu1, Xinli Mao5, Shenkang Zhou5, Qingwei Zhao1, Hongguang Xia1,2.
Abstract
Recent studies have shown that the expression level of PD-L1 in tumor cells positively correlates with tumor metastasis and recurrence rate. The effects of post-translational modifications (PTMs) of PD-L1 are related to immunosuppression. However, the degradation of PD-L1 in cancers has not yet been sufficiently defined. Here, we identified USP21 as a novel deubiquitinase of PD-L1. Overexpression of USP21 significantly increased PD-L1 abundance while its knockdown induced PD-L1 degradation. In vitro deubiquitination assay revealed that USP21-WT, but not USP21-C221A, reduced polyubiquitin chains of PD-L1. These results highlight the role of USP21 in the deubiquitination and stabilization of PD-L1. Furthermore, we show that USP21 is the frequently amplified deubiquitinase in lung cancer, especially in lung squamous cell carcinoma, and its amplification is accompanied by upregulation of PD-L1. This study reveals the mechanism of USP21-mediated PD-L1 degradation, and suggests that USP21 might be a potential target for the treatment of lung cancer. AJTREntities:
Keywords: PD-L1; USP21; deubiquitination; immune escape; lung cancer
Year: 2021 PMID: 34956491 PMCID: PMC8661224
Source DB: PubMed Journal: Am J Transl Res ISSN: 1943-8141 Impact factor: 4.060